» Articles » PMID: 36258001

International Survey Among Surgeons on the Perioperative Management of Rectal Cancer

Overview
Journal Surg Endosc
Publisher Springer
Date 2022 Oct 18
PMID 36258001
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Several pivotal studies and international guidelines on the perioperative management of rectal cancer have been published. However, little is known about the current state of perioperative management of rectal cancer patients in clinical practice worldwide.

Methods: An online survey including 13 questions focusing on key topics related to the perioperative management of patients with rectal cancer was conducted among colorectal surgeons registered within the database of the Research Institute Against Digestive Cancer (IRCAD).

Results: A total of 535 respondents from 89 countries participated in the survey. Most surgeons worked in the European region (40.9%). Two hundred and fifty-four respondents (47.5%) performed less than 25% of surgical procedures laparoscopically. The most commonly used definition of the upper limit of the rectum was a fixed distance from the anal verge (23.4%). Magnetic resonance imaging was used to define the upper limit of the rectum by 258 respondents (48.2%). During total mesorectal excision (TME), 301 respondents (56.3%) used a high-tie technique. The most commonly constructed anastomosis was an end-to-end anastomosis (68.2%) with the majority of surgeons performing a leak test intraoperatively (88.9%). A total of 355 respondents (66.4%) constructed a diverting ostomy, and the majority of these surgeons constructed an enterostomy (82%). A total of 208 respondents (39.3%) closed a stoma within 8 weeks. Lastly, 135 respondents (25.2%) introduced a solid diet on postoperative day 1.

Conclusion: There is considerable heterogeneity in the perioperative management of rectal cancer patients worldwide with several discrepancies between current international practice and recommendations from international guidelines. To achieve worldwide standardization in rectal cancer care, further research is needed to elucidate the cause of this heterogeneity and find ways of improved implementation of best practice recommendations.

Citing Articles

Safe implementation of robotic right colectomy with intracorporeal anastomosis.

Van Eetvelde E, Violon S, Poortmans N, Stijns J, Duinslaeger M, Vanhoeij M J Robot Surg. 2022; 17(3):1071-1076.

PMID: 36566471 DOI: 10.1007/s11701-022-01514-6.


International survey among surgeons on the perioperative management of rectal cancer.

Al-Difaie Z, Okamoto N, Scheepers M, Mutter D, Stassen L, Bouvy N Surg Endosc. 2022; 37(3):1901-1915.

PMID: 36258001 DOI: 10.1007/s00464-022-09702-z.


Laparoscopic right colectomies with intracorporeal compared to extracorporeal anastomotic techniques are associated with reduced post-operative incisional hernias.

Selznick S, Levy J, Bogdan R, Hawel J, Elnahas A, Alkhamesi N Surg Endosc. 2022; 37(7):5500-5508.

PMID: 36192658 PMC: 9529334. DOI: 10.1007/s00464-022-09585-0.

References
1.
Bray F, Ferlay J, Soerjomataram I, Siegel R, Torre L, Jemal A . Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68(6):394-424. DOI: 10.3322/caac.21492. View

2.
Heald R, Husband E, Ryall R . The mesorectum in rectal cancer surgery--the clue to pelvic recurrence?. Br J Surg. 1982; 69(10):613-6. DOI: 10.1002/bjs.1800691019. View

3.
Baek J, McKenzie S, Garcia-Aguilar J, Pigazzi A . Oncologic outcomes of robotic-assisted total mesorectal excision for the treatment of rectal cancer. Ann Surg. 2010; 251(5):882-6. DOI: 10.1097/SLA.0b013e3181c79114. View

4.
Kapiteijn E, Marijnen C, Nagtegaal I, Putter H, Steup W, Wiggers T . Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med. 2001; 345(9):638-46. DOI: 10.1056/NEJMoa010580. View

5.
Fleshman J, Branda M, Sargent D, Boller A, George V, Abbas M . Effect of Laparoscopic-Assisted Resection vs Open Resection of Stage II or III Rectal Cancer on Pathologic Outcomes: The ACOSOG Z6051 Randomized Clinical Trial. JAMA. 2015; 314(13):1346-55. PMC: 5140087. DOI: 10.1001/jama.2015.10529. View